0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
Volume 13, Issue 3 (2021)
3 2021, 13(3): 195-198 |
Back to browse issues page
History
Received: 2021/08/16 | Accepted: 2021/08/5 | Published: 2021/11/10
Received: 2021/08/16 | Accepted: 2021/08/5 | Published: 2021/11/10
How to cite this article
Zaki Jafar Al-Asady A, Ali Hussein Al-Hilaly I. Using Vascular Cell Adhesion Molecule-1 as a Biomarker for Detecting Progression of Different Types of Malignant Tumors. 3 2021; 13 (3) :195-198
URL: http://ijwph.daneshafarand.org/article-3-85417-en.html
URL: http://ijwph.daneshafarand.org/article-3-85417-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Pharmacology and Toxicology Department, Faculty of Pharmacy, University of Kufa, Kufa, Iraq
2- Laboratory Investigation Department, Faculty of Science, University of Kufa, Kufa, Iraq
2- Laboratory Investigation Department, Faculty of Science, University of Kufa, Kufa, Iraq
Abstract (3442 Views)
Aims: Vascular cell adhesion molecule-1 is a transmembrane glycoprotein closely related to tumorigenicity as well as tumor metastasis. It is also a well-known candidate for detecting tumors as a very common consequence of war-related symptoms. This study was designed to investigate the probability of using a cancer biomarker (VCAM-1) as an indicator for the progression of breast, lung, and bladder cancers.
Materials & Methods: This experimental study was conducted on 15 to 89 years-old patients who attended the Middle Euphrates cancer center and the breast disease clinic in AL-Sadder Medical City teaching hospital in Al-Najaf Province, Iraq, for a checkup from September 2020 to January 2021. Eighty-eight samples were selected by random sampling method; 22 patients for each breast, lung, and bladder cancer group and 22 healthy subjects as control. An Enzyme-Linked Immunosorbent Assay (ELISA) was used to evaluate the concentration of VCAM-1. Data were analyzed by one-way ANOVA and Tukey's multiple comparison tests.
Findings: The means±SE of VCAM-1 levels in control, breast, lung, and bladder cancer groups were 42.29±3.928ng/ml, 58.12±2.357ng/ml, 66.81±4.307ng/ml, and 82.85±7.292ng/ml, respectively. Serum VCAM-1 levels increased significantly in all groups compared to the control group (p<0.05) except in breast cancer (p>0.05). There was a significant difference only between breast and bladder cancer groups (p<0.05).
Conclusion: The highest level of VCAM-1 is in the bladder cancer group; therefore, serum VCAM-1 can be used as an indicator for bladder cancer.
Materials & Methods: This experimental study was conducted on 15 to 89 years-old patients who attended the Middle Euphrates cancer center and the breast disease clinic in AL-Sadder Medical City teaching hospital in Al-Najaf Province, Iraq, for a checkup from September 2020 to January 2021. Eighty-eight samples were selected by random sampling method; 22 patients for each breast, lung, and bladder cancer group and 22 healthy subjects as control. An Enzyme-Linked Immunosorbent Assay (ELISA) was used to evaluate the concentration of VCAM-1. Data were analyzed by one-way ANOVA and Tukey's multiple comparison tests.
Findings: The means±SE of VCAM-1 levels in control, breast, lung, and bladder cancer groups were 42.29±3.928ng/ml, 58.12±2.357ng/ml, 66.81±4.307ng/ml, and 82.85±7.292ng/ml, respectively. Serum VCAM-1 levels increased significantly in all groups compared to the control group (p<0.05) except in breast cancer (p>0.05). There was a significant difference only between breast and bladder cancer groups (p<0.05).
Conclusion: The highest level of VCAM-1 is in the bladder cancer group; therefore, serum VCAM-1 can be used as an indicator for bladder cancer.
Keywords: